<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32042908</article-id>
<article-id pub-id-type="pmc">6927359</article-id>
<article-id pub-id-type="publisher-id">NG2018008888</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000378</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>91</subject>
<subject>228</subject>
<subject>234</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Critical exon indexing improves clinical interpretation of copy number variants in neurodevelopmental disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-6729-1138</contrib-id>
<name>
<surname>Wassman</surname>
<given-names>E. Robert</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>Commercial, Travel funds and consulting fees from sponsor to discuss cases with a client</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>Genomic mutation load in autism and autism spectrum disorder: use to select therapies and predict prognosis</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>1) Lineagen, Inc. (sponsor), Chief Medical Officer, 9/2015-9/2017; executive advisor 9/2017-present (unpaid except as noted above in item (3)2) Predictive Laboratories, Co-Director, 8/2019-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>1) Commercial, Novaseek Research, Medical Director, IRB2) Commercial, Genepeeks, Medical Advisor3) Commercial, Stemina, Medical Advisor4) Commercial, NuView Life Sciences, CSO, Medical advisor5) Commercial, Trend Community, Advisor6) Commercial, Phase Genomics, Medical advisor7) Non-profit, TESS Foundation, Board member</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>1) Lineagen, Inc., salary and stock options2) Predictive Laboratories, salary and stock options</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>1) Lineagen2) NuView Life Sciences3) Predictive Laboratories</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>1) Lineagen2) NuView Life Sciences3) Predictive Laboratories</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>Consultant for law firms/insurers involved in asbestos related claims-no affidavits, depositions or testimony given</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-7514-8953</contrib-id>
<name>
<surname>Ho</surname>
<given-names>Karen S.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>(1) Pending: IDENTIFICATION OF SEIZURE SUSCEPTIBILITY REGION IN WOLF-HIRSCHHORN SYNDROME AND TREATMENT THEREOF (2) Pending: SYSTEMS, DEVICES, AND METHODS FOR CORRELATING GENOTYPIC AND PHENOTYPIC DATA (3) Pending: GENETIC MARKERS ASSOCIATED WITH ASD AND OTHER CHILDHOOD DEVELOPMENTAL DELAY DISORDERS</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>(1) Clene Nanomedicine, Head of Translational Medicine 2017- present (2) directly related to ms: Lineagen, Principal Scientist, 2011-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Lineagen sponsored the study.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>Lineagen, 2011-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bertrand</surname>
<given-names>Diana</given-names>
</name>
<degrees>MS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>(1) Lineagen, Inc, Genetic Counselor, 2015-2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-1874-9741</contrib-id>
<name>
<surname>Davis</surname>
<given-names>Kyle W.</given-names>
</name>
<degrees>ScM</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Lineagen, Inc.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Lineagen, Inc.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Lineagen, Inc. stock options.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>Lineagen, Inc. stock options</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-5780-3371</contrib-id>
<name>
<surname>Martin</surname>
<given-names>Megan M.</given-names>
</name>
<degrees>MS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Lineagen, Inc, Sr. Director Clinical Services, 8 years</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Lineagen, Inc</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>Lineagen, Inc. Stock/Stock Options, Medical Equipment &amp; Materials: Lineagen, Inc.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-6959-6389</contrib-id>
<name>
<surname>Page</surname>
<given-names>Stephanie</given-names>
</name>
<degrees>BS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Lineagen, Inc., Data analyst, October 2015 - August 2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peiffer</surname>
<given-names>Andreas</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Consult for Lineagen, Inc. Research Professor, University of Utah</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Consult for Lineagen, Inc...commercial entity</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other activities:</title>
<list-item>
<p>Contract physician, The Men's Health Center, Utah</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>Lineagen, Inc. LLC stock, stock options</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-5409-1257</contrib-id>
<name>
<surname>Prasad</surname>
<given-names>Aparna</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Lineagen, Inc, Research Geneticist, Aug 2016-June 2018,</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-1037-9304</contrib-id>
<name>
<surname>Serrano</surname>
<given-names>Moises A.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>(1)Lineagen, Lab director, 4 years</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-6814-4532</contrib-id>
<name>
<surname>Twede</surname>
<given-names>Hope</given-names>
</name>
<degrees>BS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vanzo</surname>
<given-names>Rena</given-names>
</name>
<degrees>MS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Reimbursement of travel/lodging/per diem when speaking on Lineagen related activities as an employee of the company.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Lineagen, VP of Clinical &amp; Scientific Affairs Employed 9 total years (started as a genetic counselor)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License fee payments, Technology or Inventions:</title>
<list-item>
<p>GC state licensure fees</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>I am on clinical research projects for Lineagen and have stock options in Lineagen Stock/Stock Options, Medical Equipment &amp; Materials: Lineagen's clinical testing services guide medical treatment</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-3900-2367</contrib-id>
<name>
<surname>Scherer</surname>
<given-names>Stephen W.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) Population Bio (2) Deep Genomics</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) npj Genomic Medicine, Senior Editor, 2015-present (2) G3: Genes, Genomes, Genetics, Senior Editor, 2011- present (3) Journal of Personalized Medicine, Editorial Board, 2010-Present (4) The Open Genomics Journal, Editorial Advisory Board, 2009-present (5) The Hugo Journal, Editorial Board, 2009-present (6) Genome Medicine, Editorial Board, 2008-present (7) Journal of Neurodevelopmental Disorders, Section Editor, 2008-present (8) Autism Research, Editorial Board, 2008-present (9) PathoGenetics, Editorial Board, 2008-present (10) Comparative and Functional Genomics, Editorial Board, 2007-present (11) BMC Medical Genomics, Editorial Board, 2006-present (12) Cytogenetics and Genome Research, Editorial Board, 2005-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>Method of Determining Disease Causality of Genome Mutations (Co-inventor Uddin), i. Serial No. CA 2,927,477, File date: Oct. 17, 2014; Status: Pending ii. Serial No. US 15/092,113, File date: April 6, 2016; Status: Pending</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) Genome Canada (2) Canadian Institutes of Health Research (3) Canadian Institute for Advanced Research (4) McLaughlin Centre (5) Canada Foundation for Innovation (6) Government of Ontario (7) NIH (8) Qatar National Research Fund (9) Brain Canada</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Autism Speaks SickKids Foundation SFARI</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>(1) MADR2 Tumour Suppressor Gene, Millipore Corp (2) Lafora's Disease Gene (EPM2a), Athena Diagnostics (3) Novel Lafora's Disease Gene (EPM2b), Athena Diagnostics</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-8363-7207</contrib-id>
<name>
<surname>Uddin</surname>
<given-names>Mohammed</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Non-profit, Departmental Funding for Conference</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>US patent application for classifying mutation for autism and neurodevelopmental disorders</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-2932-1807</contrib-id>
<name>
<surname>Hensel</surname>
<given-names>Charles H.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>During some of the work described in this manuscript, I was an employee of Lineagen, Inc. as Senior Manager of Research, a position I held for approximately 8.5 years. This employment ended in May of 2018.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>From May 2018 until May of 2019 I was a consultant of Lineagen, Inc.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>Lineagen, Inc. These stock options have since expired.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From Lineagen Inc. (E.R.W., K.S.H., D.B., K.W.D., M.M.M., S.P., A. Peiffer, A. Prasad, M.A.S., H.T., R.V., C.H.H.); Life Designs Ventures (E.R.W.), Park City, UT; Department of Pediatrics (K.S.H., A. Peiffer), University of Utah; The Centre for Applied Genomics (S.W.S., M.U.), The Hospital for Sick Children, Toronto, Ontario, <country>Canada</country>; Program in Genetics and Genome Biology (S.W.S), The Hospital for Sick Children; McLaughlin Centre (S.W.S), University of Toronto, Toronto, Ontario, <country>Canada;</country> and Department of Molecular Genetics (S.W.S), University of Toronto, Toronto, Ontario, <country>Canada.</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Correspondence</bold> Dr. Wassman<email>bwassman@lineagen.com</email></corresp>
<fn fn-type="financial-disclosure">
<p>Go to <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/6/e378/tab-article-info">Neurology.org/NG</ext-link> for full disclosures. Funding information is provided at the end of the article.</p>
</fn>
<fn fn-type="other" id="fn1">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn fn-type="other">
<p>The Article Processing Charge was funded by Lineagen, Inc.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>06</day>
<month>12</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>5</volume>
<issue>6</issue>
<elocation-id>e378</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2018008888.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective</title>
<p>To evaluate a new tool to aid interpretation of copy number variants (CNVs) in individuals with neurodevelopmental disabilities.</p>
</sec>
<sec>
<title>Methods</title>
<p>Critical exon indexing (CEI) was used to identify genes with critical exons (CEGs) from clinically reported CNVs, which may contribute to neurodevelopmental disorders (NDDs). The 742 pathogenic CNVs and 1,363 variants of unknown significance (VUS) identified by chromosomal microarray analysis in 5,487 individuals with NDDs were subjected to CEI to identify CEGs. CEGs identified in a subsequent random series of VUS were evaluated for relevance to CNV interpretation.</p>
</sec>
<sec>
<title>Results</title>
<p>CEI identified a total of 2,492 unique CEGs in pathogenic CNVs and 953 in VUS compared with 259 CEGs in 6,965 CNVs from 873 controls. These differences are highly significant (<italic>p</italic> &lt; 0.00001) whether compared as frequency, average, or normalized by CNV size. Twenty-one percent of VUS CEGs were not represented in Online Mendelian Inheritance in Man, highlighting limitations of existing resources for identifying potentially impactful genes within CNVs. CEGs were highly correlated with other indices and known pathways of relevance. Separately, 136 random VUS reports were reevaluated, and 76% of CEGs had not been commented on. In multiple cases, further investigation yielded additional relevant literature aiding interpretation. As one specific example, we discuss <italic>GTF2I</italic> as a CEG, which likely alters interpretation of several reported duplication VUS in the Williams-Beuren region.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Application of CEI to CNVs in individuals with NDDs can identify genes of potential clinical relevance, aid laboratories in effectively searching the clinical literature, and support the clinical reporting of poorly annotated VUS.</p>
</sec>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Neurodevelopmental disorders (NDDs) including developmental delay (DD), intellectual disability (ID), and autism spectrum disorder (ASD) are often caused by copy number variants (CNVs) in the genome.<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup> Chromosomal microarray analysis (CMA) for the detection of CNVs is the first-tier clinical diagnostic test for the evaluation of NDDs.<sup><xref ref-type="bibr" rid="R2">2</xref><xref ref-type="bibr" rid="R3">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup> CMA frequently identifies variants of uncertain significance (VUS), which limit clinical utility in such cases. Interpretation of VUS is relevant to clinical care of these children and important to their families.<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup></p>
<p>Clinical application of an ultra-high-resolution whole-genome chromosomal microarray optimized for the detection of genetic changes associated with a variety of NDDs provides an increased diagnostic yield, particularly due to careful attention to VUS of potential clinical relevance, constituting up to 67% of reported CNVs.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> These VUS could not be definitively linked to patients' neurodevelopmental traits despite extensive analysis of the extant literature using standard approaches, which include analysis of relevant gene content.<sup><xref ref-type="bibr" rid="R10">10</xref></sup></p>
<p>The recently described<sup><xref ref-type="bibr" rid="R11">11</xref><xref ref-type="bibr" rid="R12">–</xref><xref ref-type="bibr" rid="R14">14</xref></sup> identification of “critical” exons with high levels of brain expression and low mutation burden recognizes genes (e.g., <italic>OTUD7A</italic>)<sup><xref ref-type="bibr" rid="R14">14</xref></sup> that might be NDD candidate genes. This was adapted to create a categorical classification tool that focuses analysis on specific genes among many contained in CNVs, which are likely to contribute to interpretation. This tool retrospectively identified many genes that have relevant clinical literature, but had not been specifically detailed in the clinical reports previously issued. Prospective application of this tool may aid in the classification of VUS and affect diagnosis and management of a wide range of NDDs.</p>
<sec id="s1" sec-type="methods">
<title>Methods</title>
<sec id="s1-1">
<title>Patient data</title>
<p>CMA results were reviewed from 1,602 cases with clinically relevant findings from a previously described retrospective series of 5,487 consecutive patients with indications for testing for broader NDDs that includes ASD, DD, ID, multiple congenital anomaly (MCA), and seizures or combinations of these.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Medical records and indications for testing provided by referring providers were used to collect phenotype information. Subsequent to this series' analysis for critical exon genes (CEGs) prevalence, a separate group of 136 randomly selected reports of VUS was assessed to determine the impact critical exon indexing (CEI) might have on searching for the relevant literature and revised clinical reporting.</p>
</sec>
<sec id="s1-2">
<title>Standard protocol approvals, registrations, and patient consents</title>
<p>Written informed consent was obtained for all participants' data in this study. Deidentified data were collected under Western Institutional Review Board Protocol #20162032.</p>
</sec>
<sec id="s1-3">
<title>Chromosomal microarray and reporting</title>
<p>Between September 2012 and December 2015, 5,487 genomic DNAs were extracted with either a buccal swab or blood Gentra Puregene kit (Qiagen, Redwood City, CA), fragmented, labeled, and hybridized to a previously described microarray optimized for NDDs<sup><xref ref-type="bibr" rid="R9">9</xref></sup> (FSDX; Lineagen, Salt Lake City, UT) as specified by the manufacturer (Affymetrix).<sup><xref ref-type="bibr" rid="R15">15</xref></sup> Washed arrays were scanned and raw data files analyzed as CYCHP files using Chromosome Analysis Suite version 2.0.1 (Affymetrix, Santa Clara, CA) with reference genome from the Genome Reference Consortium: human build 37/human genome 19 (GRCh37/hg19). American Board of Medical Genetics and Genomics-certified cytogeneticists used established interpretation standards.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> In brief, CNVs were classified pathogenic if multiple peer-reviewed publications, representing at least 2 families indicate clinical features result from sensitivity of the region or gene(s) to dosage.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> If there was preliminary but insufficient evidence for pathogenicity, CNVs were classified as variants of unknown significance (VUS). CNVs are classified as benign and not reported if the region had been well characterized as a common variant in the general population by multiple peer-reviewed publications or by curated databases (e.g., the Database of Genomic Variants<sup><xref ref-type="bibr" rid="R16">16</xref></sup>).</p>
</sec>
<sec id="s1-4">
<title>Critical exon indexing</title>
<p>Identification of CEGs by CEI was adapted from previously described methods<sup><xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref></sup> The mutation burden of rare (&lt;0.05)<sup><xref ref-type="bibr" rid="R11">11</xref></sup> missense and loss-of-function mutations for each exon was calculated from the 1000 Genomes Project (<ext-link ext-link-type="uri" xlink:href="http://www.internationalgenome.org/">internationalgenome.org</ext-link>). The BrainSpan Atlas provided spatiotemporal exon level RNA-seq expression from 388 tissue samples from 16 brain regions of prenatal, early childhood, and adult brains from 32 postmortem donors.<sup><xref ref-type="bibr" rid="R17">17</xref></sup> Our cutoffs, which were modified for high stringency clinical translation, considered an exon critical if expressed at &gt;90th percentile throughout all 3 developmental stages, and has a mutation burden &lt;10th percentile (normalized by exon size). “Critical exon” enrichment between CNVs classified as pathogenic, VUS, or normal was tested with the Fisher exact test, Welch <italic>t</italic> test, or χ<sup>2</sup> analysis depending on the nature of the variables.</p>
<p>Online Mendelian Inheritance in Man (OMIM, <ext-link ext-link-type="uri" xlink:href="https://www.omim.org/">omim.org</ext-link>) and PubMed (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">ncbi.nlm.nih.gov/pubmed/</ext-link>) were used to search for published data and disorder associations for each CEG.</p>
<p>Ingenuity Pathway Analysis (IPA; Qiagen, Redwood City, CA)<sup><xref ref-type="bibr" rid="R18">18</xref></sup> was used to determine the association of CEGs within CNVs with known pathways based on literature-curated ontologies for genes, their functions, and their interactions. The number of CEG genes overlapping the list of curated genes identified in each pathway by IPA compared with CEGs not in a given pathway was tested statistically using a 1-tailed χ<sup>2</sup> test for each pathway.</p>
</sec>
<sec id="s1-5" sec-type="data-availability">
<title>Data availability</title>
<p>The authors take full responsibility for conduct of the research, its data, analyses, and interpretation. We have full access to the data and rights to publish any and all data, separate and apart from sponsor guidance.</p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<p>CMA results on 5,487 individuals with NDD (1,558 females and 3,929 males) on a custom microarray in a Clinical Laboratories Improvement Act certified laboratory from September 2012 to December 2015 were previously reported.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> A total of 2,105 rare CNVs (742 pathogenic and 1363 VUS) were clinically reported based on American College of Medical Genetics and Genomics Guidelines<sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup> (<xref ref-type="table" rid="T1">table 1</xref>).</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Observed distribution of CEGs in CNVs from neurodevelopmental disorder and controls</p>
</caption>
<graphic xlink:href="NG2018008888t1"></graphic>
</table-wrap>
<p>Analysis of these CNVs for CEGs yielded 2,492 unique CEGs in pathogenic CNVs and 953 in VUS, including 469 genes found in both pathogenic CNVs and VUS alike. The presence of at least 1 CEG in a CNV was significantly higher in pathogenic CNVs (69.9%) compared with either VUS (39.6%) (<italic>p</italic> &lt; 0.00001) or a control population<sup><xref ref-type="bibr" rid="R13">13</xref></sup> (11.4%) (<italic>p</italic> &lt; 0.00001). On average, there were significantly more CEGs per pathogenic variant (12) compared with VUS (1) (<italic>p</italic> &lt; 0.00001), and both contained significantly more than control's CNVs (0.17) (<italic>p</italic> &lt; 0.00001) (<xref ref-type="table" rid="T1">table 1</xref>). Because pathogenic CNVs are typically larger than VUS,<sup><xref ref-type="bibr" rid="R9">9</xref></sup> these data were normalized for CNV size, resulting in slightly more similar CEG/megabase pairs (Mbp) in pathogenic and VUS with 2.5 and 2.2 CEG/Mbp, respectively, but still significantly higher for pathogenic (<italic>p</italic> &lt; 0.0006) (<xref ref-type="table" rid="T1">table 1</xref>). Both are significantly greater than the 0.6 CEG/Mbp observed in the control population<sup><xref ref-type="bibr" rid="R13">13</xref></sup> (<italic>p</italic> &lt; 0.00001) (<xref ref-type="table" rid="T1">table 1</xref>).</p>
<p>We searched for overlaps between our list of CEGs present in clinically reported CNVs and (1) genes containing de novo variants identified in individuals with ASD<sup><xref ref-type="bibr" rid="R19">19</xref>,<xref ref-type="bibr" rid="R20">20</xref></sup> and (2) fragile X (fragile X mental retardation protein [FMRP]) target genes.<sup><xref ref-type="bibr" rid="R21">21</xref></sup> ASD candidate genes were highly represented in the list of CE genes identified in our CNVs (1,023 unique out of 2,228 candidates, <italic>p</italic> = 0.0039, Fisher exact test). Of the observed CEGs from both pathogenic and VUS, 38% overlap with known FMRP targets (<italic>p</italic> &lt; 0.00001, Fisher exact test).</p>
<p>Of the observed CEGs, 18% interact significantly in pathways with gene families that have key neurodevelopmental functions (<italic>p</italic> values &lt;1.15E-05 to 4.87E-12, 1-tailed χ<sup>2</sup>). (<xref ref-type="table" rid="T2">table 2</xref>).</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Top pathways represented in clinical copy number variants with statistical enrichment observed by segregation based on CEGs</p>
</caption>
<graphic xlink:href="NG2018008888t2"></graphic>
</table-wrap>
<p>When the CEGs in our cohort are cross-referenced to the OMIM database (<ext-link ext-link-type="uri" xlink:href="https://www.omim.org/">omim.org</ext-link>) commonly used to aid interpretations, 6.3% (158/2,492) of the unique CEGs from pathogenic CNVs and 21.0% (200/953) of those from VUS were not yet represented in OMIM.</p>
<sec id="s2-1">
<title>CEGs in VUS reports</title>
<p>These population-based observations of enrichment of CEGs in NDDs and their enrichment in relevant pathways led us to evaluate the utility of translating CEI to previous clinical reports of VUS, i.e., CNVs where board-certified analysts using external and internal clinical databases and established clinical guidelines<sup><xref ref-type="bibr" rid="R10">10</xref></sup> failed to find clearly pathogenic genes. We selected a random subset of 136 VUS reports to evaluate the potential impact of CEI on clinical reports and compared how gene content was discussed. Of these reports, 21% of VUS CEGs were not represented in OMIM, highlighting the limitations of existing resources for identifying potentially impactful genes in CNVs. Although some well-known CEGs were mentioned in reports as being potentially causal, in 76% of clinical reports (103/136), at least 1 CEG was not described specifically in the report. Targeted PubMed searches on 49 CEGs not previously commented on in clinical reports yielded 25 articles (51%) relevant for NDDs, which might aid the interpretation of these VUS.</p>
</sec>
<sec id="s2-2">
<title>CEGs within subregions of large pathogenic regions</title>
<p>VUS can occur as smaller CNVs overlapping or completely within known pathogenic CNVs. We hypothesized that CEGs within such VUS may indicate a critical region for pathogenicity in both the VUS and the larger known pathogenic CNV. As an example, several cases with small duplications interpreted clinically as VUS overlap the 7q11.23 Williams-Beuren syndrome (WBS) region, but from patients with only ASD clinically (<xref ref-type="table" rid="T3">table 3</xref>). One duplication VUS (<xref ref-type="table" rid="T3">table 3</xref>, patient 20) affects part of a single CEG, <italic>GTF2I</italic>, which encodes a multifunctional transcription factor.<sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref></sup> It also slightly overlaps a noncoding gene, <italic>LOC10192694.3</italic>, and <italic>NCF1</italic>, a gene expressed primarily in neutrophils. Two brothers (<xref ref-type="table" rid="T3">table 3</xref>, patients 23 and 24) shared a slightly larger overlapping VUS that completely duplicates <italic>GTF2I</italic> and partially including another CEG, <italic>CLIP2</italic>, and a nonCEG, <italic>GTF2IRD1</italic>. Patient 21 (<xref ref-type="table" rid="T3">table 3</xref>) has a VUS that affects <italic>GTF2I</italic>, <italic>GTF2IRD1</italic>, and <italic>LOC10192694.3</italic>. Another individual (<xref ref-type="table" rid="T3">table 3</xref>, patient 22) has a partial duplication of <italic>GTF2I</italic> that extends 1.9 Mbp proximally and includes several additional genes. Patients 25 and 26 have overlapping VUS of intermediate length. CNV coordinates and testing indications of each patient are shown in <xref ref-type="table" rid="T3">table 3</xref> and <xref ref-type="fig" rid="F1">figure</xref>. The only gene contained, wholly or partially, in all of these VUS from individuals with ASD is <italic>GTF2I</italic>, which has been previously associated with neurobehavioral and cognitive features of WBS.<sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref></sup></p>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<p>Observed variants of unknown significance copy number variants overlapping the WBS region</p>
</caption>
<graphic xlink:href="NG2018008888t3"></graphic>
</table-wrap>
<fig id="F1" orientation="portrait" position="float">
<label>Figure</label>
<caption>
<title>Map of VUS overlapping CEG GTF2I from individuals with ASD phenotypes</title>
</caption>
<graphic xlink:href="NG2018008888f1"></graphic>
</fig>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>The presence of critical genomic content within CNVs is central to clinical interpretation.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> The recognition that gene expression and conservation at the exon level opens new understanding of candidate genes also showed CEGs correlate significantly with patients with ASD and DD compared with their control siblings.<sup><xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref></sup> CEI led to the identification of the <italic>OTUD7A</italic> gene as a key phenotype regulator for 15q13.3 microdeletion syndrome<sup><xref ref-type="bibr" rid="R14">14</xref></sup> and has been cited in multiple publications across a variety of neurodevelopmental and behavioral disabilities including epilepsies, ASD, cerebral palsy, schizophrenia, and obsessive-compulsive disorder.<sup><xref ref-type="bibr" rid="R24">24</xref><xref ref-type="bibr" rid="R25">–</xref><xref ref-type="bibr" rid="R30">30</xref></sup> The application of CEI by clinical laboratories may assist clarifying pathogenicity of CNVs and expands where gene content is factored into interpretation and discussion of results with referring clinicians and families.</p>
<p>VUS remain a major challenge in clinical interpretation. VUS tend to be ultra-rare, relatively small, and encompass fewer genes than known pathogenic deletions and duplications. Improved CMAs make analytical detection of very small CNVs more robust,<sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup> increasing the number of VUS requiring analysis. Interpretation is dependent on the coincidence of multiple rare cases and their successful alignment from the literature and databases such as OMIM. Without compelling clinical case experience compared with control individuals, functional evidence, or unambiguous genotype-phenotype correlations, inferences of pathogenicity are difficult and laborious processes for the standard clinical laboratory.</p>
<p>This observational study on the prevalence of CEGs identified by CEI was conducted on CNVs found in consecutive individuals presenting with NDDs and/or MCA by CMA. In total, 2,976 unique CEGs were identified within reported CNVs. It is not particularly surprising that the CEG content of pathogenic CNVs is significantly higher than in VUS or CNVs in controls, given the literature on CEI to date,<sup><xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R24">24</xref><xref ref-type="bibr" rid="R25">–</xref><xref ref-type="bibr" rid="R30">30</xref></sup> (<xref ref-type="table" rid="T1">table 1</xref>); however, it is of interest that whether looked at in terms of CNVs with at least one CEG (<italic>p</italic> &lt; 0.00001), average number per CNV (<italic>p</italic> &lt; 0.00001), or CEG/Mbp basis (<italic>p</italic> &lt; 0.00001) in VUS is also significantly higher than is controls, too. It is perhaps noteworthy than when adjusted for size differences in VUSs, the CEGs/Mbp are more similar with 2.5 vs 2.2 per Mbp (<italic>p</italic> = 0.0006) for pathogenic and VUS, respectively, than when compared in terms of overall prevalence (<italic>p</italic> &lt; 0.0001). This supports possible clinical relevance in some VUS, as does the overlapping presence of 469 specific CEGs (18.8% of 2,492) in both pathogenic and VUS CNVs. We suggest that this supports their importance in the VUS potential for pathogenicity and may therefore aid interpretation.</p>
<p>CEI on a subsequent random set of clinical reports issued by the same clinical laboratory showed that 76% (103/136) failed to mention at least one of these potentially important genes. Of CEGs from VUS, 21% (200/953) were not represented in OMIM at the time but may well be in the future as the clinical literature evolves. Further targeted PubMed searches of VUS CEGs yielded articles relevant for NDDs in many. This gap between clinical reporting of rare events and genes that segregate in terms of frequency between affected and control populations highlights the value of this CEI to assessment of VUS.</p>
<p>Of the observed CEGs, 18% interact in pathways with gene families that have key neurodevelopmental functions (<italic>p</italic> values: &lt;1.15E-05 to 4.87E-12, χ<sup>2</sup> test) (<xref ref-type="table" rid="T2">table 2</xref>). Of the observed CEGs from both pathogenic and VUS CNVs, 38% overlap with known FMRP targets (<italic>p</italic> &lt; 0.00001), which are believed to be associated with NDDs, and some are now targets of directed drug development.</p>
<p>Comparison to genes containing de novo variants identified in individuals with ASD<sup><xref ref-type="bibr" rid="R19">19</xref></sup> showed a statistically significant representation of the CEGs in the clinically reported CNVs (<italic>p</italic> = 0.0039). As the research literature suggests, these overlapping genes could represent causal genes lying within the larger pathogenic CNVs.<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R24">24</xref><xref ref-type="bibr" rid="R25">–</xref><xref ref-type="bibr" rid="R30">30</xref></sup></p>
<p>Clinical genomic literature does not always include discussion of VUS, and clinical reporting is inconsistent within and across laboratories as guidelines<sup><xref ref-type="bibr" rid="R10">10</xref></sup> focus on clinically definitive findings. In the context of genomic testing of affected individuals, the a priori significance of VUS is different than in the predictive setting, e.g., cancer predisposition, and may be relevant to both clinician's management and family perceptions.<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R8">8</xref></sup> Over time, further clinical experience will eventually allow for reclassification of many VUS as either benign or pathogenic; however, the rarity of these sometimes “private” genetic findings delays their clinical utility. As an independent and nonoverlapping resource, CEI can focus the efforts of cytogeneticists and others interpreting test results on specific genes within CNVs rather than the affected region in total or the comprehensive list of the genes affected, and this can aid in the determination of pathogenicity of a VUS.</p>
<p>Another strategy using a model trained on nonpathogenic deletions in the general population has been applied to attempt to estimate the effect size of pathogenic deletions and correlate quantitatively the effects of haploinsufficiency on Intelligence Quotient (IQ). This approach may also help predict the impact of VUS in NDD; however, studies to date have exclusively evaluated deletions and largely focus on size alone<sup><xref ref-type="bibr" rid="R33">33</xref></sup> rather than specific genomic content as prescribed by interpretive guidelines.<sup><xref ref-type="bibr" rid="R10">10</xref></sup> The databases available to clinical laboratories to interpret genomic content, including CNVs, are constantly improving and expanding. Notably, the Exome Aggregation Consortium created a metric based on the probability of loss of function (pLI) of the protein products of genes in that database for similar filtering of candidate disease-causing variants. A pLI ≥ 0.9 is considered “high” and serves as a cutoff to separate genes of sufficient length into loss of function intolerant,<sup><xref ref-type="bibr" rid="R34">34</xref></sup> and we are studying the application of “high pLI” now as a nonredundant resource along with CEI for clinical interpretation.</p>
<p>Finally, we describe a specific example in this series where several clinically reported VUS overlap a single well-known CEG, <italic>GTF2I</italic>. This gene is located within the Williams-Beuren 7q11.23 microdeletion-duplication syndrome region, which contains nearly 100 other genes.<sup><xref ref-type="bibr" rid="R22">22</xref></sup> However, our VUS cases show a remarkable phenotype-genotype consistency (ASD) distinct from these well-described syndromes. Dosage of the <italic>GTF2I</italic> gene has been proposed to be responsible for the differing neurobehavioral phenotypes of WBS and the 7q11.23 microduplication syndrome.<sup><xref ref-type="bibr" rid="R22">22</xref>,<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R35">35</xref><xref ref-type="bibr" rid="R36">–</xref><xref ref-type="bibr" rid="R39">39</xref></sup> Individuals with partial WBS deletions that do not include <italic>GTF2I</italic> are reported without ID, but typically have the WBS-associated visual-spatial cognition impairment.<sup><xref ref-type="bibr" rid="R39">39</xref></sup>
<italic>GTF2I</italic> mediates oxytocin reactivity, and individuals with WBS have elevated oxytocin levels, whereas unaffected individuals with different polymorphisms in <italic>GTF2I</italic> manifest varying oxytocin levels, which correspond with their self-reported levels of social anxiety.<sup><xref ref-type="bibr" rid="R36">36</xref>,<xref ref-type="bibr" rid="R37">37</xref></sup>
<italic>GTF2I</italic> encodes a multifunctional transcription factor, a gene class previously associated with NDDs,<sup><xref ref-type="bibr" rid="R35">35</xref><xref ref-type="bibr" rid="R36">–</xref><xref ref-type="bibr" rid="R39">39</xref></sup> and specific single nucleotide polymorphisms are associated with ASD.<sup><xref ref-type="bibr" rid="R38">38</xref></sup>
<italic>GTF2I</italic> is the only gene contained, wholly or partially, in all of these VUS, suggesting that its partial or complete duplication might be responsible for ASD features noted. The additional cases identified here by application of CEI merit reassessment of these CNVs and correlating phenotypes for pathogenicity.</p>
<p>CEI pinpointed clinically relevant genes in VUS and streamlined the identification of citations relevant to the patients' indications for testing. Such relevant literature adds to VUS reports and keys in on potentially critical genes that may define pathogenicity. CEI also has the potential to identify networks and pathways of relevant genes shared within one CNV or across several CNVs in a single individual or in multiple individuals. By narrowing down the list of genes within the breakpoints of CNVs, CEI could aid assessment of “multiple-hit” interactions. This could target potential drug development for some individuals with NDDs who share common causal networks and pathways, which otherwise might not be evident.</p>
<p>Of course, there are limitations and caveats to this approach. CEI as described defines CEGs as those that contain exons with high brain expression or genes with at least 1 splice isoform that is highly expressed in the brain. Genes that do not display this exact expression profile, i.e., ubiquitously expressed in the body but still perform an essential brain development function, would not be identified as a CEG despite potential importance to the etiology of NDDs, e.g., <italic>MECP2</italic> (Rett syndrome). These could represent false-negative results; however, the CEI tool is always used in conjunction with other methods, and well-described genes should not in fact be missed in analysis. Similarly, some CNVs common in the general population do also harbor CEGs, such as <italic>BTRC</italic> and <italic>ZNF90</italic>, both CEGs, but apparently commonly duplicated or deleted. Whether these CEGs are simply not dose sensitive or whether they only affect NDD etiology when combined with “second hits” (single nucleotide variants in other genes, rare unreported CNVs, or structural variants not detected by CMA) remains to be determined. The cross-referencing of databases should identify these as exceptions and not cause a false-positive misinterpretation.<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R16">16</xref></sup></p>
<p>As whole-exome/genome sequencing becomes more commonly used clinically,<sup><xref ref-type="bibr" rid="R40">40</xref></sup> and the analytical capability of these tools to accurately detect CNVs improves<sup><xref ref-type="bibr" rid="R41">41</xref></sup> the challenge of interpreting VUS and apparent “multi-hit” situations grows and should similarly be aided by CEI. Further assessment of this tool is therefore warranted, while cautiously applying its demonstrated strengths in enhancing the clinical interpretation of rare CNVs.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgment</title>
<p>The authors thank Dr. Patricia Mowery-Rushton, Dr. Colleen Bilancia, Dr. Ankita Patel, and the entire Lineagen clinical team for helpful discussions. SWS is supported by The Centre for Applied Genomics, the University of Toronto McLaughlin Centre, and the GlaxoSmithKline-CIHR Endowed Chair in Genome Sciences at SickKids and the University of Toronto. This work has been presented in part at the NSGC and ASHG annual meetings in 2017 and 2016.</p>
</ack>
<sec sec-type="funding">
<title>Study funding</title>
<p content-type="funding">Lineagen, Inc.; S.W. Scherer is supported by The Centre for Applied Genomics, the University of Toronto McLaughlin Centre, and the GlaxoSmithKline-CIHR Endowed Chair in Genome Sciences at SickKids and the University of Toronto.</p>
</sec>
<sec sec-type="disclosure">
<title>Disclosure</title>
<p content-type="disclosure">Disclosures available: <ext-link ext-link-type="uri" xlink:href="https://ng.neurology.org/content/5/6/e378/tab-article-info">Neurology.org/NG</ext-link>.</p>
</sec>
<app-group>
<app id="A1">
<label>Appendix</label>
<title>Authors</title>
<p>
<table-wrap id="TU1" orientation="portrait" position="anchor">
<graphic xlink:href="NG2018008888tu1"></graphic>
<graphic xlink:href="NG2018008888tu1a"></graphic>
</table-wrap>
</p>
</app>
</app-group>
<glossary>
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1">ASD</term>
<def>
<p>autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term id="G2">CEG</term>
<def>
<p>critical exon gene</p>
</def>
</def-item>
<def-item>
<term id="G3">CEI</term>
<def>
<p>critical exon indexing</p>
</def>
</def-item>
<def-item>
<term id="G4">CMA</term>
<def>
<p>chromosomal microarray analysis</p>
</def>
</def-item>
<def-item>
<term id="G5">CNV</term>
<def>
<p>copy number variant</p>
</def>
</def-item>
<def-item>
<term id="G6">DD</term>
<def>
<p>developmental delay</p>
</def>
</def-item>
<def-item>
<term id="G7">FMRP</term>
<def>
<p>fragile X mental retardation protein</p>
</def>
</def-item>
<def-item>
<term id="G8">ID</term>
<def>
<p>intellectual disability</p>
</def>
</def-item>
<def-item>
<term id="G9">IPA</term>
<def>
<p>ingenuity pathway analysis</p>
</def>
</def-item>
<def-item>
<term id="G10">Mbp</term>
<def>
<p>megabase pairs</p>
</def>
</def-item>
<def-item>
<term id="G11">MCA</term>
<def>
<p>multiple congenital anomaly</p>
</def>
</def-item>
<def-item>
<term id="G12">NDD</term>
<def>
<p>neurodevelopmental disorder</p>
</def>
</def-item>
<def-item>
<term id="G13">OMIM</term>
<def>
<p>Online Mendelian Inheritance in Man</p>
</def>
</def-item>
<def-item>
<term id="G14">pLI</term>
<def>
<p>probability of loss of function index</p>
</def>
</def-item>
<def-item>
<term id="G15">VUS</term>
<def>
<p>variants of unknown significance</p>
</def>
</def-item>
<def-item>
<term id="G16">WBS</term>
<def>
<p>Williams-Beuren syndrome</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iafrate</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Feuk</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rivera</surname><given-names>MN</given-names></name>, <etal>et al</etal></person-group>
<article-title>Detection of large-scale variation in the human genome</article-title>. <source/>Nat Genet
<year>2004</year>;<volume>36</volume>:<fpage>949</fpage>–<lpage>951</lpage>.<pub-id pub-id-type="pmid">15286789</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>DT</given-names></name>, <name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Aradhya</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies</article-title>. <source/>Am J Hum Genet
<year>2010</year>;<volume>86</volume>:<fpage>749</fpage>–<lpage>764</lpage>.<pub-id pub-id-type="pmid">20466091</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaefer</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Mendelsohn</surname><given-names>NJ</given-names></name></person-group>
<article-title>Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions</article-title>. <source/>Genet Med
<year>2013</year>;<volume>15</volume>:<fpage>399</fpage>–<lpage>407</lpage>.<pub-id pub-id-type="pmid">23519317</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volkmar</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Siegel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Woodbury-Smith</surname><given-names>M</given-names></name>, <name name-style="western"><surname>King</surname><given-names>B</given-names></name>, <name name-style="western"><surname>McCracken</surname><given-names>J</given-names></name>, <name name-style="western"><surname>State</surname><given-names>M</given-names></name></person-group>
<article-title>Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder</article-title>. <source/>J Am Acad Child Adolesc Psychiatry
<year>2014</year>;<volume>53</volume>:<fpage>237</fpage>–<lpage>257</lpage>.<pub-id pub-id-type="pmid">24472258</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moeschler</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Shevell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Saul</surname><given-names>RA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comprehensive evaluation of the child with intellectual disability or global developmental delays</article-title>. <source/>Pediatrics
<year>2014</year>;<volume>134</volume>:<fpage>e903</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">25157020</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kearney</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>South</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Wol</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Lamb</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hamosh</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>KW</given-names></name></person-group>
<article-title>American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities</article-title>. <source/>Genet Med
<year>2011</year>;<volume>13</volume>:<fpage>676</fpage>–<lpage>679</lpage>.<pub-id pub-id-type="pmid">21681105</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bernhardt</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Mulchandani</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>“What does it mean?”: uncertainties in understanding results of chromosomal microarray testing</article-title>. <source/>Genet Med
<year>2012</year>;<volume>14</volume>:<fpage>250</fpage>–<lpage>258</lpage>.<pub-id pub-id-type="pmid">22241091</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jez</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>South</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vanzo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Rothwell</surname><given-names>E</given-names></name></person-group>
<article-title>Variants of unknown significance on chromosomal microarray analysis: parental perspectives</article-title>. <source/>J Community Genet
<year>2015</year>;<volume>6</volume>:<fpage>343</fpage>–<lpage>349</lpage>.<pub-id pub-id-type="pmid">25666435</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Twede</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Vanzo</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Real-world clinical performance of an ultra-high resolution chromosomal microarray optimized for neurodevelopmental disorders</article-title>. <source/>Biomed Res Int
<year>2016</year>;<volume>2016</volume>:<fpage>3284534</fpage>.<pub-id pub-id-type="pmid">27975050</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>South</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lamb</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Higgins</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Kearney</surname><given-names>HM</given-names></name></person-group>; <collab>Working Group for the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee</collab>. <article-title>ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013</article-title>. <source/>Genet Med
<year>2013</year>;<volume>15</volume>:<fpage>901</fpage>–<lpage>909</lpage>.<pub-id pub-id-type="pmid">24071793</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tammimies</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pellecchia</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder</article-title>. <source/>Nat Genet
<year>2014</year>;<volume>46</volume>:<fpage>742</fpage>–<lpage>747</lpage>.<pub-id pub-id-type="pmid">24859339</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pellecchia</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Thiruvahindrapuram</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Indexing effects of copy number variation on genes involved in developmental delay</article-title>. <source/>Sci Rep
<year>2016</year>;<volume>6</volume>:<fpage>28663</fpage>.<pub-id pub-id-type="pmid">27363808</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Thiruvahindrapuram</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>A high-resolution copy-number variation resource for clinical and population genetics</article-title>. <source/>Genet Med
<year>2015</year>;<volume>17</volume>:<fpage>747</fpage>–<lpage>752</lpage>.<pub-id pub-id-type="pmid">25503493</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uddin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Unda</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Kwan</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>
<article-title>OTUD7A regulates neurodevelopmental phenotypes in the 15q13.3 microdeletion syndrome</article-title>. <source/>Am J Hum Genet
<year>2018</year>;<volume>102</volume>:<fpage>278</fpage>–<lpage>295</lpage>.<pub-id pub-id-type="pmid">29395074</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason-Suares</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Grimmett</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Density matters: comparison of array platforms for detection of copy-number variation and copy-neutral abnormalities</article-title>. <source/>Genet Med
<year>2013</year>;<volume>15</volume>:<fpage>706</fpage>–<lpage>712</lpage>.<pub-id pub-id-type="pmid">23558256</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Ziman</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Yuen</surname><given-names>RK</given-names></name>, <etal>et al</etal></person-group>
<article-title>The Database of Genomic Variants: a curated collection of structural variation in the human genome</article-title>. <source/>Nucleic Acids Res
<year>2014</year>; <volume>42</volume>(<issue>Database issue</issue>):<fpage>D986</fpage>–<lpage>D992</lpage>.<pub-id pub-id-type="pmid">24174537</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sunkin</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system</article-title>. <source/>Nucleic Acids Res
<year>2013</year>;<volume>41</volume>(<issue>Database issue</issue>):<fpage>D996</fpage>–<lpage>D1008</lpage>.<pub-id pub-id-type="pmid">23193282</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krämer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pollard</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tugendreich</surname><given-names>S</given-names></name></person-group>
<article-title>Causal analysis approaches in ingenuity pathway analysis</article-title>. <source/>Bioinformatics
<year>2014</year>;<volume>30</volume>:<fpage>523</fpage>–<lpage>530</lpage>.<pub-id pub-id-type="pmid">24336805</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuen</surname><given-names>RKC</given-names></name>, <name name-style="western"><surname>Merico</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bookman</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder</article-title>. <source/>Nat Neurosci
<year>2017</year>;<volume>20</volume>:<fpage>602</fpage>–<lpage>611</lpage>.<pub-id pub-id-type="pmid">28263302</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iossifov</surname><given-names>I</given-names></name>, <name name-style="western"><surname>O'Roak</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Sanders</surname><given-names>SJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>The contribution of de novo coding mutations to autism spectrum disorder</article-title>. <source/>Nature
<year>2014</year>;<volume>515</volume>:<fpage>216</fpage>–<lpage>221</lpage>.<pub-id pub-id-type="pmid">25363768</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Darnell</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Van Driesche</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name></person-group>
<article-title>FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism</article-title>. <source/>Cell
<year>2011</year>;<volume>146</volume>:<fpage>247</fpage>–<lpage>261</lpage>.<pub-id pub-id-type="pmid">21784246</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakurai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dorr</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Takahashi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>McInnes</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Elder</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Buxbaum</surname><given-names>JD</given-names></name></person-group>, <article-title>Haploinsufficiency of GTF2I, a gene deleted in Williams syndrome, leads to increases in social interactions</article-title>. <source/>Autism Res
<year>2011</year>;<volume>4</volume>:<fpage>28</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">21328569</pub-id></mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crespi</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Hurd</surname><given-names>PL</given-names></name></person-group>
<article-title>Cognitive-behavioral phenotypes of Williams syndrome are associated with genetic variation in the GTF2I gene, in a healthy population</article-title>. <source/>BMC Neurosci
<year>2014</year>;<volume>15</volume>:<fpage>127</fpage>.<pub-id pub-id-type="pmid">25429715</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ruppert</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Trucks</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>
<article-title>Burden analysis of rare microdeletions suggests a strong impact of neurodevelopmental genes in genetic generalised epilepsies</article-title>. <source/>PLoS Genet
<year>2015</year>;<volume>11</volume>:<fpage>e1005226</fpage>.<pub-id pub-id-type="pmid">25950944</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gazzellone</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Lionel</surname><given-names>AC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Copy number variation in Han Chinese individuals with autism spectrum disorder</article-title>. <source/>J Neurodev Disord
<year>2014</year>;<volume>6</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">25170348</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo exon 1 deletion of AUTS2 gene in a patient with autism spectrum disorder and developmental delay: a case report and a brief literature review</article-title>. <source/>Am J Med Genet A
<year>2015</year>;<volume>167</volume>:<fpage>1381</fpage>–<lpage>1385</lpage>.<pub-id pub-id-type="pmid">25851617</pub-id></mixed-citation>
</ref>
<ref id="R27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lowther</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Speevak</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Armour</surname><given-names>CM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Molecular characterization of NRXN1 deletions from 19,263 clinical microarray cases identifies exons important for neurodevelopmental disease expression</article-title>. <source/>Genet Med
<year>2017</year>;<volume>19</volume>:<fpage>53</fpage>.<pub-id pub-id-type="pmid">27195815</pub-id></mixed-citation>
</ref>
<ref id="R28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarrei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fehlings</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Mawjee</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy</article-title>. <source/>Genet Med
<year>2018</year>;<volume>20</volume>:<fpage>172</fpage>–<lpage>180</lpage>.<pub-id pub-id-type="pmid">28771244</pub-id></mixed-citation>
</ref>
<ref id="R29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <etal>et al</etal></person-group>
<article-title>Increased co-expression of genes harboring the damaging de novo mutations in Chinese schizophrenic patients during prenatal development</article-title>. <source/>Scientific Rep
<year>2015</year>;<volume>5</volume>:<fpage>18209</fpage>.</mixed-citation>
</ref>
<ref id="R30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gazzellone</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Zarrei</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Burton</surname><given-names>CL</given-names></name>, <etal>et al</etal></person-group>
<article-title>Uncovering obsessive-compulsive disorder risk genes in a pediatric cohort by high-resolution analysis of copy number variation</article-title>. <source/>J Neurodev Disord
<year>2016</year>;<volume>8</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">27777633</pub-id></mixed-citation>
</ref>
<ref id="R31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Merico</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Thiruvahindrapuram</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>A discovery resource of rare copy number variations in individuals with autism spectrum disorder</article-title>. <source/>G3 (Bethesda)
<year>2012</year>;<volume>2</volume>:<fpage>1665</fpage>–<lpage>1685</lpage>.<pub-id pub-id-type="pmid">23275889</pub-id></mixed-citation>
</ref>
<ref id="R32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucker</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Montpetit</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chai</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comparison of genome-wide array genomic hybridization platforms for the detection of copy number variants in idiopathic mental retardation</article-title>. <source/>BMC Med Genomics
<year>2011</year>;<volume>4</volume>:<fpage>25</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">21439053</pub-id></mixed-citation>
</ref>
<ref id="R33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huguet</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schramm</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Douard</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Measuring and estimating the effect sizes of copy number variants on general intelligence in community-based samples</article-title>. <source/>JAMA Psychiatry
<year>2018</year>;<volume>75</volume>:<fpage>447</fpage>–<lpage>457</lpage>.<pub-id pub-id-type="pmid">29562078</pub-id></mixed-citation>
</ref>
<ref id="R34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Minikel</surname><given-names>EV</given-names></name>, <etal>et al</etal></person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature
<year>2016</year>;<volume>536</volume>:<fpage>285</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="R35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borralleras</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sahun</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Pérez-Jurado</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Campuzano</surname><given-names>V</given-names></name></person-group>
<article-title>Intracisternal GTF2I gene therapy ameliorates deficits in cognition and synaptic plasticity of a mouse model of williams-Beuren syndrome</article-title>. <source/>Mol Ther
<year>2015</year>;<volume>23</volume>:<fpage>1691</fpage>–<lpage>1699</lpage>.<pub-id pub-id-type="pmid">26216516</pub-id></mixed-citation>
</ref>
<ref id="R36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Ying</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bellugi</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Pournajafi-Nazarloo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Korenberg</surname><given-names>JR</given-names></name></person-group>
<article-title>Oxytocin and vasopressin are dysregulated in Williams syndrome, a genetic disorder affecting social behavior</article-title>. <source/>PLoS One
<year>2012</year>;<volume>7</volume>:<fpage>e38513</fpage>.<pub-id pub-id-type="pmid">22719898</pub-id></mixed-citation>
</ref>
<ref id="R37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Procyshyn</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Spence</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Read</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Watson</surname><given-names>NV</given-names></name>, <name name-style="western"><surname>Crespi</surname><given-names>BJ</given-names></name></person-group>
<article-title>The Williams syndrome prosociality gene <italic>GTF2I</italic> mediates oxytocin reactivity and social anxiety in a healthy population</article-title>. <source/>Biol Lett
<year>2017</year>;<volume>13</volume>:<fpage>20170051</fpage>.<pub-id pub-id-type="pmid">28424317</pub-id></mixed-citation>
</ref>
<ref id="R38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malenfant</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hudson</surname><given-names>ML</given-names></name>, <etal>et al</etal></person-group>
<article-title>Association of GTF2I in the Williams-Beuren syndrome critical region with autism spectrum disorders</article-title>. <source/>J Autism Dev Disord
<year>2012</year>;<volume>42</volume>:<fpage>1459</fpage>–<lpage>1469</lpage>.<pub-id pub-id-type="pmid">22048961</pub-id></mixed-citation>
</ref>
<ref id="R39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name></person-group>
<article-title>Role of splice variants of GTF2I, a transcription factor localizing at postsynaptic sites, and its relation to neuropsychiatric diseases</article-title>. <source/>Int J Mol Sci
<year>2017</year>;<volume>18</volume>:<fpage>E411</fpage>.<pub-id pub-id-type="pmid">28212274</pub-id></mixed-citation>
</ref>
<ref id="R40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Love-Nichols</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Dies</surname><given-names>KA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders</article-title>. <source/>Genet Med
<year>2019</year>;<volume>21</volume>:<fpage>2413</fpage>–<lpage>2421</lpage>.<pub-id pub-id-type="pmid">31182824</pub-id></mixed-citation>
</ref>
<ref id="R41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trost</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name></person-group>
<article-title>A comprehensive workflow for read depth-based identification of copy-number variation from whole-genome sequence data</article-title>. <source/>Am J Hum Genet
<year>2018</year>;<volume>102</volume>:<fpage>142</fpage>–<lpage>155</lpage>.<pub-id pub-id-type="pmid">29304372</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>